Flare-Up Phenomenon of Intradermal Test with Anaphylactic Reaction to Paracetamol (Acetaminophen)

Page: [69 - 72] Pages: 4

  • * (Excluding Mailing and Handling)

Abstract

Background: Paracetamol is a Non-Steroidal Anti-Inflammatory Drug (NSAID) that can produce hypersensitive reactions mediated by specific immunological mechanisms (IgE or T celldependent) or by a non-immunological mechanism (inhibition of cyclooxygenase COX-1).

Objective: An 80-year-old man with a history of allergy to pyrazolones, with good tolerance to other NSAIDs was referred to our allergy department because he presented a generalized urticaria after the administration of Intravenous (IV) paracetamol.

Methods: We performed an Intradermal Test (IDT) with paracetamol (0.02mg/ml) and later a Single Blind Oral Challenge Test (SBOCT) with oral paracetamol.

Results: IDT reading at 15min showed negative result so an SBOCT was performed with oral paracetamol. With an accumulative dose of 250mg, after 20min, he developed discomfort, nausea and dizziness, urticarial, hypotension (BP 80/40) as well as flare-up phenomenon was observed in the site of the IDT with paracetamol. Tryptase levels during the reaction and 2hrs later were increased.

Conclusion: We present an anaphylactic shock due to sensitization to paracetamol because of a type I hypersensitivity mechanism, diagnosed by SBOCT and a positive IDT because of flare-up phenomenon, in a patient with previous pyrazolones allergy and with tolerance to other NSAIDs. Some relevant patents are also summarized in this paper.

Keywords: Acetylsalicylic acid (ASA), intradermal test (IDT), intravenous (IV), non-steroidal anti-inflammatory drug (NSAID), single-blind oral challenge test (SBOCT), subcutaneous (SC).

[1]
Gabrielli S, Langlois A, Ben-Shoshan MM. Prevalence of hypersensitivity reactions in children associated with acetaminophen: A systematic review and meta-analysis. Int Arch Allergy Immunol 2018; 176(2): 106-14.
[2]
De Paramo BJ, Gancedo SQ, Cuevas M, Camo IP, Martin JA, et al. Paracetamol (acetaminophen) hypersensitivity. Ann Allergy Asthma Immunol 2000; 85: 508-11.
[3]
Bachmeyer C, Vermeulen C, Habki R, Blay F, Leynadier FS. Acetaminophen (paracetamol) induced anaphylactic shock. South Med J 2002; 95: 759-60.
[4]
Rojas-Perez-Ezquerra P, Sanchez-Morillas L, Gomez-Traseira C, Gonzalez-Mendiola R, Alcorta-Valle AR, Laguna-Martinez J. Selective hypersensitivity reactions to acetaminophen: A 13-case series. J Allergy Clin Immunol In Pract 2014; 2: 343-5.
[5]
Martin JA, Lazaro M, Cuevas M, Alvarez-Cuesta E. Paracetamol anaphylaxis. Clin Exp Allergy 1993; 23: 534-8.
[6]
Rutkowski SM, Nasser PW, Ewan S. Paracetamol hypersensitivity: Clinical features, mechanism and role of specific IgE. Int Arch Allergy Immunol 2012; 159: 60-4.
[7]
Galindo PA, Borja J, Mur P, Feo F, Gómez E, García R. Anaphylaxis to paracetamol. Allergol Immunopathol (Madr) 1998; 26: 199-200.
[8]
Reig Rincon de Arellano I, Villalón García AL, Cimarra Alvarez-Lovell M, Robledo-Echarren T, Martínez-Cocó MC. Flare up to betalactams. Allergol Immunopathol (Madr) 2005; 33: 282-4.
[9]
González de Olano D, González Mancebo E, Gandolfo Cano M, Menéndez Baltanás A, Trujillo Trujillo MJ. Flare-up-like phenomenon in a skin prick test after oral challenge with ibuprofen. J Investig Allergol Clin Immunol 2007; 17: 414-5.
[10]
Duvall RN, Gold G. Effervescent cold or sinus allergy medicine composition having reduced sodium content. EP0418564 1991.
[11]
Andreatta P. Method for preparing an effervoscent granulate, granulate thus obtained and pharmaceutical forms containing it. EP1004292. (2000).
[12]
Muñoz FH, Plágaro RF. Injectable liquid paracetamol formulation. WO2008009756 2008.
[13]
Grattan TJ. Swallow tablet comprising paracetamol. US7993673 (2011).
[14]
Anderson JC, Hsiau T, Srivastava S, Ruan P, Prakash I, Kotker J. Method for biosynthesis of acetaminophen. WO2016069155 (2016).
[15]
Carvajal ML, Asensio JC, Tirado FJ. Novel dispersible and soluble galenic paracetamol formulation, method for its preparation and its applications. WO2002036101. (2002).
[16]
Toulia KT. Pharmaceutical injectable solutions containing paracetamol and combinations of paracetamol with other active substances. EP0916347 (1999).